PAS
PBYI icon

Point72 Asia (Singapore)’s Puma Biotechnology PBYI Stock Holding History

Point72 Asia (Singapore)’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-38,346
Closed -$203K – 1390
2024
Q1 		$203K Buy
38,346
+37,450
+4,180% +$202K 0.05% 423
2023
Q4 		$3.88K Buy
+896
New +$2.97K ﹤0.01% 543

Other funds holding PBYI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
ACM
Athyrium Capital Management New York $8.69M AUM 34.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Point72 Asia (Singapore)'s PBYI Position: Q2 2024 in Review

Point72 Asia (Singapore) sold out of Puma Biotechnology (PBYI) in Q2 2024, closing a stake of 38,346 shares — an estimated $203K sold.

Point72 Asia (Singapore) first reported a position in PBYI in Q4 2023 and held it in 2 quarters. The position peaked at $203K in Q1 2024. 99 funds tracked by Wall St. Rank hold PBYI as of Q2 2024.

  • Point72 Asia (Singapore) reported no remaining Puma Biotechnology position as of Q2 2024 after selling out during the quarter.
  • Point72 Asia (Singapore) sold 38,346 Puma Biotechnology shares in Q2 2024, an estimated $203K.
  • Point72 Asia (Singapore) first reported a position in Puma Biotechnology in Q4 2023 and held it in 2 quarters.
  • Point72 Asia (Singapore)'s Puma Biotechnology position peaked at $203K in Q1 2024.
  • 99 funds tracked by Wall St. Rank held Puma Biotechnology as of Q2 2024.

Based on Point72 Asia (Singapore)'s 13F filing for Q2 2024, filed 14 Aug 2024.